About>Our Team

Mike Serrano-Wu, Ph.D.

Chief Scientific Officer

Michael Serrano-Wu has been a key driver for several first-in-class drug discovery efforts.  At BMS, he catalyzed the nascent field of HCV NS5A-based therapy by designing the first known palindromic inhibitor, leading to the discovery of daclatasvir and an entire class of follow-on drugs.  Later at Novartis, Mike led the team which discovered pradigastat, a DGAT1 inhibitor currently in clinical investigation.

Mike received his A.B. and Ph.D. in Organic Chemistry from Harvard University.

  • For partnerships, investment opportunities, or to learn more about our work, contact us.